Fibroblast growth factor homologous factor-1 (FHF-1) and methods of use

Abstract

A novel protein, fibroblast growth factor homologous factor-1 (FHF-1), the polynucleotide sequence encoding FHF-1, and the deduced amino acid sequence are disclosed. Also disclosed are diagnostic and therapeutic methods of using the FHF-1 polypeptide and polynucleotide sequences and antibodies which specifically bind to FHF-1.

1 . Substantially pure fibroblast growth factor homologous factor-1 (FHF-1) characterized by: 
 a. having a molecular weight of about 30 kD as determined by reducing SDS-PAGE; and    b. having essentially the amino acid sequence of SEQ ID NO:2.    
     
     
         2 . An isolated polynucleotide sequence encoding the FHF-1 polypeptide of  claim 1 .  
     
     
         3 . The polynucleotide of  claim 2 , wherein the FHF-1 nucleotide sequence is selected from the group consisting of: 
 a. SEQ ID NO:1, wherein T can also be U;    b. nucleic acid sequences complementary to SEQ ID NO:1;    c. fragments of a. or b. that are at least 15 bases in length and that will selectively hybridize to DNA which encodes the FHF-1 protein of SEQ ID NO:2, under stringent conditions.    
     
     
         4 . The polynucleotide sequence of  claim 2 , wherein the polynucleotide is isolated from a mammalian cell.  
     
     
         5 . The polynucleotide of  claim 4 , wherein the mammalian cell is a human cell.  
     
     
         6 . An expression vector including the polynucleotide of  claim 2 .  
     
     
         7 . The vector of  claim 6 , wherein the vector is a plasmid.  
     
     
         8 . The vector of  claim 6 , wherein the vector is a virus.  
     
     
         9 . A host cell stably transformed with the vector of  claim 6 .  
     
     
         10 . The host cell of  claim 9 , wherein the cell is prokaryotic.  
     
     
         11 . The host cell of  claim 9 , wherein the cell is eukaryotic.  
     
     
         12 . An antibody that binds to FHF-1 polypeptide or immunoreactive fragments thereof.  
     
     
         13 . The antibody of  claim 12 , wherein the antibody is polyclonal.  
     
     
         14 . The antibody of  claim 12 , wherein the antibody is monoclonal.  
     
     
         15 . A method of detecting a cell proliferative disorder comprising contacting a specimen of a subject suspected of having a FHF-1 associated cell proliferative disorder with a reagent that binds to FHF-1 and detecting binding of the reagent to FHF-1.  
     
     
         16 . The method of  claim 15 , wherein the cell is selected from the group consisting of brain, testes or eye cell.  
     
     
         17 . The method of  claim 15 , wherein the reagent is an antibody which binds to FHF-1.  
     
     
         18 . The method of  claim 15 , wherein the reagent is a polynucleotide which encodes FHF-1 polypeptide, or fragments thereof.  
     
     
         19 . The method of  claim 15 , wherein the detecting is in vivo.  
     
     
         20 . The method of  claim 15 , wherein the detection is in vitro.  
     
     
         21 . The method of  claim 17  or  18 , wherein the reagent is detectably labeled.  
     
     
         22 . The method of  claim 21 , wherein the detectable label is selected from the group consisting of a radioisotope, a fluorescent compound, a bioluminescent compound and a chemiluminescent compound.  
     
     
         23 . A method of treating a cell proliferative disorder associated with expression of FHF-1, comprising contacting the cell having or suspected of having the disorder with a reagent which suppresses the FHF-1 activity.  
     
     
         24 . The method of  claim 23 , wherein the reagent is an anti-FHF-1 antibody.  
     
     
         25 . The method of  claim 23 , wherein the reagent is a FHF-1 antisense sequence.  
     
     
         26 . The method of  claim 23 , wherein the cell is a testes, brain or eye cell.  
     
     
         27 . The method of  claim 23 , wherein the reagent which suppresses FHF-1 activity is introduced to the cell using a vector.  
     
     
         28 . The method of  claim 27 , wherein the vector is a colloidal dispersion system.  
     
     
         29 . The method of  claim 28 , wherein the colloidal dispersion system is a liposome.  
     
     
         30 . The method of  claim 29 , wherein the liposome is essentially target specific.  
     
     
         31 . The method of  claim 30 , wherein the liposome is anatomically targeted.  
     
     
         32 . The method of  claim 30 , wherein the liposome is mechanistically targeted.  
     
     
         33 . The method of  claim 32 , wherein the mechanistic targeting is passive.  
     
     
         34 . The method of  claim 32 , wherein the mechanistic targeting is active.  
     
     
         35 . The method of  claim 34 , wherein the liposome is actively targeted by coupling with a moiety selected from the group consisting of a sugar, a glycolipid, and a protein.  
     
     
         36 . The method of  claim 35 , wherein the protein moiety is an antibody.  
     
     
         37 . The method of  claim 27 , wherein the vector is a virus.  
     
     
         38 . The method of  claim 37 , wherein the virus is an RNA virus.  
     
     
         39 . The method of  claim 38 , wherein the RNA virus is a retrovirus.  
     
     
         40 . The method of  claim 39 , wherein the retrovirus is essentially target specific.